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Background: Interferon regulatory factor (IRF)-5 is a transcription factor involved in type I interferon signaling
whose germ line variants have been associated with autoimmune pathogenesis. Since relationships have been
observed between development of autoimmunity and responsiveness of melanoma to several types of
immunotherapy, we tested whether polymorphisms of IRF5 are associated with responsiveness of melanoma to
adoptive therapy with tumor infiltrating lymphocytes (TILs).
Methods: 140 TILs were genotyped for four single nucleotide polymorphisms (rs10954213, rs11770589, rs6953165,
rs2004640) and one insertion-deletion in the IRF5 gene by sequencing. Gene-expression profile of the TILs, 112
parental melanoma metastases (MM) and 9 cell lines derived from some metastases were assessed by Affymetrix
Human Gene ST 1.0 array.
Results: Lack of A allele in rs10954213 (G >A) was associated with non-response (p < 0.005). Other polymorphisms
in strong linkage disequilibrium with rs10954213 demonstrated similar trends. Genes differentially expressed in vitro
between cell lines carrying or not the A allele could be applied to the transcriptional profile of 112 melanoma
metastases to predict their responsiveness to therapy, suggesting that IRF5 genotype may influence immune
responsiveness by affecting the intrinsic biology of melanoma.
Conclusions: This study is the first to analyze associations between melanoma immune responsiveness and IRF5
polymorphism. The results support a common genetic basis which may underline the development of
autoimmunity and melanoma immune responsiveness.Introduction
The development of autoimmunity in patient with ma-
lignant melanoma has been linked to tumor regression
following immunotherapy with interleukin (IL)-2, inter-
feron (IFN)α or anti-Cytotoxic T-Lymphocyte Antigen
(CTLA)-4. Examples include hypothyroidism [1,2],
vitiligo [3], anti-phospholipids syndrome [4] and auto-
immune retinopathy [5]. In particular, the fact that effective
immune responses against melanoma are associated with
the development of vitiligo [3], which results from auto-
immune destruction of normal melanocytes, reinforces* Correspondence: uccellinilorenzo@gmail.com; fmarincola@mail.cc.nih.gov
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reproduction in any medium, provided the orthe pathogenic commonality between autoimmunity
and cancer rejection.
Several studies support the hypothesis that distinct
immune-mediated tissue-specific destruction (TSD) pro-
cesses such as autoimmunity, cancer rejection, allograft
rejection, graft versus host disease, or acute infection
resulting in clearance of pathogens share convergent
final mechanisms [6-9]; we have previously defined this
phenomenon as the immunological constant of rejection
(ICR) [6]. The ICR includes the coordinate expression of
genes controlling antigen presentation, interferon-
stimulated genes (ISGs) and immune effectors functions
(IEFs). The suggestion that the phenomena of immune-
mediated cancer rejection and autoimmunity represent
different faces of TSD, leads to the conjecture that fac-
tors responsible for autoimmunity might also be relevant
to the immunotherapy of cancer.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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for systemic autoimmune disease. An important step to
understand the pathogenesis of SLE was the appreciation
for the dominant role played by type I IFNs [10,11]. Var-
iants of genes within the IFN pathway like interferon
regulatory factor (IRF)-5 have been associated with SLE
by multiple studies [12,13] and have been repeatedly
implicated in susceptibility to several other autoimmune
diseases including rheumatoid arthritis [14], multiple
sclerosis [15,16], inflammatory bowel disease [17] and
Sjogren’s syndrome [12,18]. IRF5 is involved in host
defense against pathogens by inducing transcription of
IFNα [19] and the expression of genes involved in apop-
tosis [20,21]. Three functional variants of IRF5 that are
associated with SLE risk have been touted to define the
risk to develop SLE: including a splice site, a 30 base pair
in-frame insertion/deletion, and an alternative polyade-
nylation site in the 3’UTR region [22]; however, no fine
mapping study has been reported to establish whether
these, over the many other variants, including an inter-
esting promoter variant [23] are preferred as explana-
tions for SLE risk.
The prominent role played by IRF5 variants in deter-
mining the risk to develop autoimmunity suggests a
possible role for IRF5 as modulator of immune respon-
siveness of melanoma. However, to our knowledge, IRF5
polymorphisms have never been studied in the context
of melanoma. Therefore, we investigated whether poly-
morphisms in IRF5 associated to SLE are also associated
with melanoma responsiveness to immunotherapy. Con-
cordant to results obtained in SLE, the lack of the A
allele in rs10954213 (G>A) that is protective against the
development of SLE was associated to non-responsiveness
to treatment among 140 patients with metastatic melanoma
who received the adoptive transfer of tumor infiltrating
lymphocytes (TILs). Remarkably, transcriptional changes
observed between melanoma cell lines carrying or not the
A allele could be used to predict responsiveness of 112
melanoma metastases (MM), suggesting that the IRF5-
dependent immune responsiveness is at least partly related
to the intrinsic biology of melanoma.
Materials and methods
Patient samples
TILs were expanded in vitro from 140 excised melanoma
metastases for reinfusion into patients following lympho-
depletion of the host. An aliquot from each TIL prepar-
ation were cryo preserved on the day of infusion.
Samples were collected during 5 consecutive trials at the
Surgery Branch, National Cancer Institute (NCI) [24,25].
Before TIL administration, patients received nonmyeloa-
blative lymphodepletion consisting of cyclophosphamide
at 60 mg/Kg/d for 2 days and fludarabine at 25 mg/m2/d
for 5 days [24]. Two Gy or 12 Gy total body irradiation(TBI) was administered in conjunction with chemother-
apy in T200 and T1200 trials, respectively. Within 1 day
of completion of lymphodepletion, TILs were infused
and high-dose IL-2 therapy was started (720,000 IU/Kg
intravenously every 8 hours to tolerance). Two days after
TIL infusion, patients treated with TBI also received au-
tologous purified CD34+ hematopoietic stem cells from
a granulocyte colony-stimulating factor ± plerixafor.
Different protocols were employed to generate TILs
[24-26]. A ‘classic’ method employing an extended dur-
ation of multiple microcultures and an individualized
assay to identify tumor recognition was used for TNMA,
T200, T1200 trials [24,26]. A simplified method using
short-term cultured ‘young’ TILs unscreened for tumor-
reactivity were used in TYT and TCD8 trials [25]. TILs
were depleted from CD4+ cells in TCD8 trial [25].
Inclusion criteria for the trials were: age ≥ 18, measur-
able disease, good clinical performance and a life expect-
ancy above 3 months. All patients signed an informed
consent approved by the NCI Institutional Review
Board. Data for this analysis are updated as of January
11th, 2012. Response (complete response CR, partial re-
sponse PR or no response NR) was assessed using the
Response Evaluation Criteria in Solid Tumors (RECIST)
guidelines starting approximately 4 weeks after TIL ad-
ministration and at regular intervals thereafter. A CR or
PR was considered an overall response (R).
TIL samples from 142 melanoma patients under adop-
tive transfer therapy were available: RNA and DNA were
isolated from the same 140 TIL with 2 additional TIL
for RNA only. 112 pre-treatment snap-frozen tumor bi-
opsies used for the TIL generation were used for RNA
extraction. RNA and DNA were also isolated from 15
melanoma cell lines derived from the 112 melanoma
lesions.
Genotyping
Four single nucleotide polymorphisms (SNPs) rs10954213,
rs11770589, rs6953165, rs2004640 and one insertion-
deletion in exon 6 of IRF5 were genotyped by sequen-
cing 140 TILs. PCR was carried out in a reaction
mixture containing 40 ng of DNA, 10 μl of HotStar
Taq Master Mix (Qiagen, Germantown, MD) and 100
pmol of each of the following primers: for rs10954213/
rs11770589, forward 5-CCCTGATTTCCCTGGTTTG-3
and reverse 5’-AGCCAGCCAGGTGAGTGTT-3’; for
rs6953165/rs2004640 forward 5’-CACCGCAGACAGG
TGGG-3’, reverse 5’-GGGAGGCGCTTTGGAAGT-3’; for
insertion-deletion in exon 6 forward 5’-CCCCACATGAC
ACCCTATTC-3’ and reverse 5’-GGCTGGGGTCTGG
AGCAG-3’. The reaction mixture was denatured at 95°C
for 15 minutes and cycled 35 times at 94°C for 45 seconds,
Ta for 45 seconds (Ta = 55°C for rs10954213 / rs11770589;
Ta = 56°C for rs6953165 / rs2004640; Ta = 58°C for
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sion at 72°C for 10 minutes. PCR product was treated
with Exosap-IT (USB Corporation, Cleveland, OH) to
removed excess primers. 3.5 μl out of 20 of purified DNA
product was combined with 2.0 μl of Big Dye terminator
(ABI Prism Big Dye Terminator cycle sequencing ready
reaction kit v3.1, Applied Biosystems, Foster City, CA)
and 100 pmol of forward primer. The sequencing reaction
was carried out for 30 cycles of denaturation (96°C/1 m),
annealing (50°C/30 s) and extension (60°C/ 4 m). Excess
dye terminators were removed using DyeEx 96 Kit
columns as per Manufacturer’s instructions (Qiagen Inc.
Germantown, MD). Electrophoresis was performed on ABI
Prism 3730 XL instrument (Applied Biosystems, Foster
City, CA).
Statistical analysis
In this explorative analysis, no stratification of patients
was done according to distinct TIL protocols with the as-
sumption that the genetic background of the patient
would have an independent effect on responsiveness to
the conceptually similar therapeutic protocols studied
here. Association analyses were conducted by chi-square
test using 2 × 2 and 2 × 3 contingency tables. When 1 or
more variables in the contingency table were≤ 5, Fisher’s
exact test was used. Two side probability values
(p2-value) < 0.05 were considered to be statistically signifi-
cant. In gene expression data analysis, the variance of the
log-intensity for each gene was compared to the median
of all the variances. Those genes not significantly more
variable than the median gene were filtered out (p> 0.01).
For class comparison in cell lines with replicates, a linear
mixed-effects model was used for each gene (implemented
in BRB-ArrayTools). Cell line was specified as random ef-
fect and IFNα and genotype were specified as fixed factors.
Genes that were differentially expressed between genotype
“A” and “G” groups were identified after accounting for
the differences in expression in IFNα+ and IFNα- groups.
A list of genes whose expression changes due to IFNα
were also identified by adjusting for any imbalances in the
“A” to “G” ratio in the IFNα+ and IFNα- groups. To con-
firm the segregation of two distinct groups in class com-
parison analysis data, a K-means clustering algorithm was
performed that chooses a pre-specified number of cluster
centers to minimize the within class sum of squares from
those centers [27].
Calculation of linkage disequilibrium (LD) para-
meters (r2 and D’) based on genotype data from 140
patients was performed using LDPlotter tool from
https://pharmgat.org/Tools.
Gene expression profiling
We generated 3 independent gene expression data sets
from 140 TIL samples, 112 melanoma metastases and 9cell lines out of 15 that were homozygous for a given
IRF5 haplotype and had been expanded from some of
the metastases. Total RNA was extracted using
miRNeasy minikit (Qiagen, Germantown, MD). The cell
lines were treated with 1000 U/mL IFNα2b and RNA
was isolated after 9 hours. RNA quality and quantity was
estimated using Nanodrop (Thermo Scientific, Wilmington,
DE) and Agilent 2100 Bioanalyzer (Agilent Technologies,
Palo Alto, CA). RNA was amplified from 300 ng of total
RNA (Ambion WT Expression Kit). cDNA was reverse
transcribed with biotinilation and hybridized to the
GeneChip Human Gene 1.0 ST Arrays (Affymetrix WT
Terminal Labeling Kit,) after fragmentation. The arrays
were washed and stained on a GeneChip Fluidics Station
450 (Affymetrix, Santa Clara, CA); scanning was carried
out with the GeneChip Scanner 3000 and image analysis
with the Affymetrix GeneChip Command Console Scan
Control. Expression data were normalized using the
RMA algorithm, http://www.partek.com (Partek Inc., St.
Louis, MO and log-transformed (base 2) for parametric
analysis and cluster analysis was based on Partek soft-
ware. Functional interpretations were based on Ingenuity
Pathways Analysis software (http://www.ingenuity.com
(Ingenuity Systems, Inc., Redwood City, CA).
Results
Genotyping results
Genotyping of TILs – Sequencing germline DNA extracted
from 140 TILs for IRF5 rs10954213, rs11770589 and
rs6953165, rs2004640 and one insertion-deletion in exon 6
demonstrated that genotype frequency distribution was
significantly different between responders and non-
responders (Table 1). All IRF5 variants but rs2004640 were
associated with immune responsiveness. The lack of the A
allele in rs10954213 was predominant in non-responders
(rs10954213: AA+AG: 63R vs. 50NR, GG: 7R vs. 20NR,
P=0.005), (Table 2). All investigated polymorphisms but
rs2004640 are in LD with each other in both responders
and non-responders (r2 = 1, D’=1, Figure 1). Because of
the strong linkage disequilibrium among the different var-
iants, we selected one (rs10954213) that provided the high-
est predictive value for subsequent class comparison
analyses as representative of the IRF5 extended haplotype.
Moreover, because the presence of the A allele in this SNP
was associated with immune responsiveness independent
of homo/hetorozygosity, we split samples into an “A” allele
carrier (AA+AG) and an “A” allele missing (GG) group.
Genotyping of cell lines – all the 15 cell lines were gen-
otyped for rs10954213 (G >A) polymorphism to test the
degree in which this trait was conserved within the
instable genetic background of cancer cells. All of the
cell lines displayed the genetic profile predicted by the
germline analysis with the exception of one (3025 Mel),
which demonstrated loss of heterozygosis (LOH, loss of
Table 1 IRF5 genotype frequencies
Genotype R NR #total P
rs10954213 AA 33 (63.5) 19 (36.5) 52 (37.1) 0.007
AG 30 (49.2) 31 (50.8) 61(43.6)
GG 7 (25.9) 20 (74.1) 27 (19.3)
rs1177589 AA 18 (60) 12 (40) 30 (21.4) 0.012
AG 39 (57.4) 29 (42.6) 68 (48.6)
GG 13 (31) 29 (69) 42 (30)
rs2004640 GG 16 (43.2) 21 (56.8) 37 (26.5) 0.6219
GT 34 (53.2) 30 (46.8) 64 (45.7)
TT 20 (51.2) 19 (48.8) 39 (27.8)
rs6953165 CC 66 (60) 57 (40) 123 (87.9) 0.059
CG 4 (57.4) 12 (42.6) 16 (11.4)
GG 0 (31) 1 (69) 1 (0.7)
exon6 del/del 18 (60) 12 (40) 30 (21.4) 0.011
ins/del 39 (57.4) 29 (42.6) 68 (480.6)
ins/ins 13 (31) 29 (69) 42 (30)
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significant because it leads to the absence of the domin-
ant “A” allele determining immune responsiveness. For
this reason, although the patient bore a mixed genotype,
the hemi-zygotic “G” cell line was considered together
with the “G” homozygous cell lines for class comparison.
However, the patient and corresponding tumor were
considered still heterozygous because there is no clear
evidence that the cell line genotype was representative
of the cancer cells in vivo, nor it was known whether the
transcriptional profile of tumors containing a mixed
population of cancer and normal cells would be predom-
inantly affected by one or the other. In addition, it is not
known whether the IRF5 genotype of the tumor or some
other cell type, such as an immune cell, is where the
genotype is relevant to the immune-responsiveness
phenotype. Certainly, if there an elevated proportion of
patients have metastases showing loss of heterozygosity
the “A” allele at IRF5, then this would imply that the
IRF5 genotype of the tumor itself is important. In any
case, the frequency of LOH was < 10%. Thus, we esti-
mated, for the purpose of further analysis, that the geno-
type of cancer cells in tumor tissues was conserved in
approximately 90% of cases and conducted further classTable 2 IRF5 rs10954213-TILs association
Genotype R NR Total P
AA+AG 63 (55.8) 50 (44.2) 113 (81.0) 0.005
GG 7 (25.9) 20 (74.1) 27 (19.0)
140 (100)comparisons classifying metastases according to the gen-
etic background of the corresponding patient.Gene expression profiling
Cell lines
Nine of the 15 cell lines generated from the melanoma
metastases were analyzed for functional differences
according to their IRF5 genotype; the genetic profile of
these cell lines and its relationship with the parental
tumors has been extensively described elsewhere [28]. To
test whether differences between IRF5 genotype bear any
effects on the intrinsic biology of cancer cells without the
influence of the microenvironment, we cultured the 9 cell
lines with or without IFNα and compared transcriptional
patterns according to their IRF5 rs10954213 genotype.
Seven cell lines out of the 15 bore the more frequent “AA”
genotype but one of them stopped growing in culture, re-
ducing to 6 the number of cell line analyzed; whereas
three (including the “G” hemizygous cell line) bore only
the GG allele. Principal Component Analysis (PCA)
(Figure 2) demonstrated that identical cell lines distribu-
ted closely in three-dimensional spaces independently of
the treatment with IFNα with the three G only carrying
cell lines clustering close together. IFNα predicatively
affected the expression of 1,411 genes (p < 0.01), mostly
related to IFN signaling (see Additional file 1: Table S1).
We identified 106 differentially expressed genes between
“A” and “G” groups using a linear mixed-effects model
(p < 0.01). Gene enrichment analysis suggested that the
predominantly affected pathways were related to antigen
presentation, immune response, allograft rejection, auto-
immunity and metabolism.Re-clustering of melanoma metastases based on transcripts
differentiating melanoma cell lines with distinct IRF5
genotype
The 106 gene signature differentiating melanoma cell
lines in vitro was applied to produce a heat map of mel-
anoma metastases based on K mean clustering method
(Figure 3). This experiment identified a subset of metas-
tases significantly enriched in non-responders. Interest-
ingly, while this signature appeared to strongly predict
lack of immune responsiveness, it was less predictive of
the IRF5 genotype of the patient, suggesting that the re-
lationship between the two parameters is complex and
multifactorial. K-means clustering algorithm, performed
on the class comparison of metastases based on tran-
scripts differentiating melanoma cell lines with distinct
IRF5 genotype, segregated two groups of patients. The
group 2 includes 46 responders and 32 non-responders,
while the group 1 includes 12 responders and 22 non-
responders, with in this case inclusion of a large majority






























































Figure 1 (Left) Pairwise linkage disequilibrium between IRF5 polymorphisms in tumor infiltrating lymphocytes (TILs). D’ and r2 were
calculated using LDPlotter tool. D’ values for linkage disequilibrium among the major alleles of each of IRF5 are shown. IN-DEL= insertion/
deletion. (Right) Samples studied: 140 TILs, 112 parental melanoma metastases and 9 cell lines derived from some metastases.
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Several studies support a link between autoimmunity
and cancer immune responsiveness, suggesting that the
two phenomena share a common determinism. Thus,
we hypothesized that factors relevant to autoimmunity
might also be relevant to cancer immunotherapy. The
IRF5 gene has been associated with SLE in multiple eth-
nic groups and repeatedly implicated in susceptibility toTable 3 Fifteen melanoma cell lines genotype compared
with the germline
Cell lines ID rs10954213 (G>A)
Melanoma cell lines Germline
TIL_120 3104 AA AA
TIL_064 2458 AA AA
TIL_121 3107 AA AA
TIL_030 2155 AA AA
TIL_077 2744 AA AA
TIL_048 2492 AA AA
TIL_047 2448 AA AA
TIL_032 2224 AG AG
TIL_062 2523 AG AG
TIL_013 2035 AG AG
TIL_040 2427 AG AG
TIL_016 2075 AG AG
TIL_109 3025 YG (LOH)* AG
TIL_005 1866 GG GG
TIL_088 2805 GG GG
*LOH=Loss Of Heterozygosis.many autoimmune diseases, becoming a rationale for
the focus of our study. Consistent with the concept that
autoimmunity and cancer rejection might represent dif-
ferent facets of the same phenomenon, we observed that
polymorphisms protecting against the susceptibility to
develop SLE [12,13], such as the IRF5 rs10954213 GG
genotype, were significantly more prevalent among
patients who did not respond to adoptive TIL therapy.
We analyzed cell lines grown from 9 metastases to test
the weight of the IRF5 genotype on the intrinsic biology
of cancer cells independent of microenvironment influ-
ences. This allowed us to test the ability of the IRF5
genotype to predict immune responsiveness in vivo. We
applied the signatures of genes differentiating the 2 cell
line genotypes in vitro to the melanoma metastases
in vivo and observed a significant segregation of respon-
ders from non-responders, leading to the conclusion
that immune responsiveness is at least in part dependent
upon the genetic background of the host, which affects
the biology of cancer cells primarily, and secondarily the
immune responsiveness of tumors.
It is interesting to observe that the IRF5 genotype
appeared to segregate 2 different cases. When genes dif-
ferentiating melanoma cell lines in vitro according to
genotype were applied for class prediction, a segregation
of responding and non responding cases was observed
and it was only partially predictive of the IRF5 genotype
in vivo. The resulting segregation of cases according to
genotype was associated with likelihood of responsive-
ness. However, there were cases lacking the genetic
background predictive of susceptibility to therapy that
still did not respond to the treatment. This is a classic
linear mixed-effects model Interferon AA vs. GG
p<0.01 1411 106





• 1866  • 2155
• 2458  • 2492
• 2744  • 2805
• 3025  • 3104
• 3107
Figure 2 (Top panel) Principal Component Analysis (PCA) based on the gene expression profile of 9 out of 15 melanoma cell lines. The
3D displays of the PCA are color coded by sample ID, IFNα treatment, and IRF5 genotype, respectively. (Bottom panel) Gene expression analysis
of cell lines using linear mixed-effects model shows 106 genes were found significant (p < 0.01) for testing the genotype effect and 1411 genes
were found significant (p < 0.01) for testing the interferon effect.
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siveness [29] underlining that multiple factors may be
necessary to allow response to therapy, among which
the host genetic background is one. Thus, it is possible
that this separate set of genes has distinct yet comple-
mentary influences on immune responsiveness.
Fine mapping studies now underway suggest that there
are two independent associations with IRF5 defining risk
for lupus (L. Kottyan, J. Harley, K.M. Kaufman, unpub-
lished data). The markers identified as being associated
with the responses to TILs in this study are more asso-
ciated with the association located in the promoter of
IRF5. In addition, in lupus there are suggestive data that
sub-phenotypes also have variable associations with IRF5
alleles [30], suggesting rich variation in the IRF5 control
of immune responsiveness.TUMORS
Cell line profile defining 
IRF5 genotype (p<0.01)
Figure 3 Cell lines predict tumor behavior, comparing AA vs GG. K m
clustered based on 106 genes differentiating melanoma cell lines with dist
metastases significantly enriched in non-responders; on the left side of the
value = 0.025).As a theoretical limitation of this study, we refrained
from genotyping the melanoma metastases with the as-
sumption that polymorphisms of the germline were suf-
ficiently representative. Due to the genetic instability of
the tumor genome, genotyping the tumor DNA instead
of the germline DNA would be ideal for association
studies. However, tumor tissue samples are composed of
heterogeneous cell types and it is not clear which one
mostly contributes to immune responsiveness. Thus, this
study was aimed only at the predictive effects of the gen-
etic background of the host. On the other hand, com-
parison of 15 cell lines with their parental tumors
suggested that in the large majority of cases the IRF5
gene was conserved. The frequency of LOH was < 10%,
which is close to other estimates of LOH prevalence for
genes not directly related to oncogenesis such as theean clustering method organize heat map of melanoma metastases re-
inct IRF5 genotype. On the right side of the panel, a subset of
panel, a set of cases that enriched in responders (Fisher test: p2-
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are confident that this analysis approximates the results
that could be obtained if the analysis could have been
adjusted according to potential somatic changes in the
IRF5 gene.
In conclusion, polymorphism of IRF-5 appears to be a
predictor of immune responsiveness of melanoma me-
tastases to adoptive therapy with TILs. Comparison of
melanoma cell lines classified according to the AA vs.
GG rs10954213 (G >A) suggested significant differences
in global transcription enriched in genes related to im-
mune regulation. The signatures differentiating the 2 cell
line genotypes in vitro are predictive of the responsive-
ness of melanoma metastases in vivo. Thus, it appears
that immune responsiveness is at least in part dependent
on the genetic background of the host, which affects the
biology of cancer cells primarily and secondarily the im-
mune responsiveness of tumors. This is the first study
analyzing the role of IRF5 gene polymorphism in deter-
mining immune responsiveness of melanoma. The
results provide a link between the determinism of auto-
immunity and immune responsiveness and suggest a po-
tential genetic marker that could be evaluated
prospectively and eventually considered for future pa-
tient stratification.
Additional file
Additional file 1: Table S1. Table of significant genes for testing
'genotype' effect (106 genes were found significant at level 0.01).
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